Results 61 to 70 of about 2,707 (157)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis

Drug Design, Development and Therapy, 2015
John D Szumowski,1,2 John B Lynch11Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; 2Division of AIDS Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA Abstract: New approaches
Szumowski JD, Lynch JB
doaj  

Systematic Review on 1,2,3‐Oxadiazoles, 1,2,4‐Oxadiazoles, and 1,2,5‐Oxadiazoles in the Antimycobacterial Drug Discovery

ChemMedChem, Volume 20, Issue 9, May 5, 2025.
The review focuses on relationships of oxadiazole derivative structures and their antimycobacterial activity including target structures in mycobacteria, in vitro or in vivo pharmacokinetic parameters, and toxicity. Apart from direct antimycobacterial activity, some 1,2,4‐oxadiazole derivatives can potentiate the antimycobacterial effect of ethionamide
Marta Kučerová‐Chlupáčová
wiley   +1 more source

Delamanid expanded access novel treatment of drug resistant tuberculosis

Infection and Drug Resistance, 2015
Roxana Rustomjee,1 Alimuddin Zumla2,31South African Medical Research Council, Cape Town, South Africa; 2Division of Infection and Immunity, University College London, London, UK; 3NIHR Biomedical Research Centre, University College Hospitals NHS ...
Rustomjee R, Zumla A
doaj  

Effect of delamanid on interim outcomes of bacteriological conversion amongst pediatric drug resistant tuberculosis cases in India

Lung India
Aim: To determine the bacteriological conversion rate after 6 months of Delamanid (DLM) based treatment in children with drug-resistant tuberculosis (DR-TB) and determine factors associated with bacteriological conversion.
Dhruv Kalawadia, Darshini Gandhi, Tsering Y Dirkhipa, Akanksha Jaiswal, Daksha Shah, Jyoti Salve, Malik Parmar, Kuldeep S Sachdeva, Minnie Bodhanwala, Ira Shah   +9 more
doaj   +1 more source

Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Clinical Pharmacology &Therapeutics, Volume 117, Issue 5, Page 1292-1302, May 2025.
The complexity of the currently registered dosing schedules for bedaquiline and delamanid is a barrier to uptake in drug‐resistant tuberculosis treatment across all ages. A simpler once‐daily dosing schedule is critical to ensure patient‐friendly regimens with good adherence. We assessed expected drug exposures with proposed once‐daily doses for adults
Yu‐Jou Lin, Louvina E. van der Laan, Mats O. Karlsson, Anthony J. Garcia‐Prats, Anneke C. Hesseling, Elin M. Svensson   +5 more
wiley   +1 more source

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations

Drug Design, Development and Therapy, 2016
Minhui Hu,1 Chunlan Zheng,1 Feng Gao2 1Department of Internal Medicine – Section 5, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute), 2Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of ...
Hu MH, Zheng CL, Gao F
doaj  

Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance Mycobacterium tuberculosis in Shanghai, China

Infection and Drug Resistance, 2023
Yinjuan Guo,1 Jinghui Yang,1 Weiping Wang,1 Xiaocui Wu,1 Baoshan Wan,1 Hongxiu Wang,1 Wei Sha,2 Fangyou Yu1 1Department of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China ...
Guo Y, Yang J, Wang W, Wu X, Wan B, Wang H, Sha W, Yu F   +7 more
doaj  

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China

International Journal of Infectious Diseases, 2019
Objective: Hong Kong is a high-income city of China with an intermediate tuberculosis (TB) burden, and 1% of TB cases are multidrug-resistant (MDR-TB).
Qianqian Fan, Wai-kit Ming, Wai-ying Yip, Joyce H.S. You   +3 more
doaj   +1 more source

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

BMC Infectious Diseases, 2019
Background At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaquiline and delamanid was a critical development in the MDR-TB treatment ...
Uzma Khan, Helena Huerga, Aamir J. Khan, Carole D. Mitnick, Catherine Hewison, Francis Varaine, Mathieu Bastard, Michael Rich, Molly F. Franke, Sidney Atwood, Palwasha Y. Khan, Kwonjune J. Seung   +11 more
doaj   +1 more source

The role of delamanid in the treatment of drug-resistant tuberculosis

Therapeutics and Clinical Risk Management, 2015
Joseph M Lewis,1 Derek J Sloan2,3 1Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK; 2Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK; 3Liverpool Heart and Chest Hospital, Liverpool, UK ...
Lewis JM, Sloan DJ
doaj